Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tiumeq

- PMLiVE

FDA approves Olysio/Sovaldi combination in hep C

Janssen drug recommended for use along with Gilead’s blockbuster

- PMLiVE

117,000 hepatitis C patients receive Sovaldi so far

Breakthrough drug has made $8.5bn for Gilead this year

EU flag

EC: medicines to remain part of health directorate

Juncker U-turns on decision to move pharma oversight to enterprise and industry

- PMLiVE

GSK to sell off part of its HIV venture ViiV Healthcare

And sets out new restructure programme as US Seretide sales hit

- PMLiVE

Russian HIV vaccine heading for phase II trials

But trials could be affected by lack of funding

Gilead Sciences

Gilead gets US approval for Sovaldi follow-up Harvoni

Company claims it could cure 90 percent of patients within eight weeks

- PMLiVE

EMA draws fire on new clinical reports policy

Has recently come under pressure from transparency groups

EU flag

EMA backs 15 new medicines for use in EU

Includes new treatments from Gilead, Lilly, Boehringer, AstraZeneca and Janssen

- PMLiVE

Gilead will file safer HIV combination before year-end

New version of Stribild is less likely to cause side effects

EU flag

EC slammed for pharma oversight changes

Organisations criticise decision to transfer responsibility for pharma policy from health to industrial department

European Commissioner for health and food safety elected

Vytenis Andriukaitis will take on the role from October

- PMLiVE

H4B’s charity team launches Catalyst4Change

The comms agency aims to 'help smaller charities be heard'

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links